Quantum-Si Incorporated (QSI) — Titan Protect Analysis

QSI

Quantum-Si Incorporated

Healthcare · ·

$1.05

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$260M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-3.32

Based on estimated future earnings — lower means cheaper

Rev Growth

-69.4%

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-46.4%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$2.50

+138% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 3 analysts covering this stock

About Quantum-Si Incorporated

Quantum-Si incorporated, a life sciences company, develops proprietary, universal, and single-molecule detection platform applied to proteomics to enable next-gen protein sequencing (NGPS). The company offers Platinum and Platinum Pro NGPS instruments for single-molecule, amino acid level resolution, and automated data analysis; library preparation kits to prepare a customer's protein sample for sequencing; and sequencing kits, which contain the reagents and consumables used to perform NGPS. It

https://www.quantum-si.com

Country: United States Employees: 145 Industry: Medical Devices

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

0.583

Good returns relative to risk taken

Kelly Fraction

0.0280

Modest edge detected — smaller position warranted

Calmar Ratio

-0.121

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-10.1%

Historical annualised return based on price data

Max Drawdown

-83.4%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

3.16

Significantly more volatile than the market

52W High

$3.10

66% below the year high

52W Low

$0.69

52% above the year low

Avg Volume

5,312,984

Average daily shares traded — higher means easier to buy and sell

Short Ratio

3.4

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.50

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

1.85

Meaningful debt load — monitor closely

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

40.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-9,322.9%

Profit from core operations before interest and tax

Free Cash Flow

$-45,931,124

Negative — the business is spending more than it generates

Revenue (TTM)

$2M

Total revenue over the last 12 months

Net Income

$-103,821,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$4.00

Target Median

$2.50

Target Low

$1.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go